COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 1955: Articles 19541-19550  | Next

Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos.
Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W. L., Ademuyiwa, A. O., Omilabu, S. A.
10.1101/2021.01.05.21249131 — Posted: 2021-01-06 Discussion: Onsite
Impaired performance of SARS-CoV-2 antigen-detecting rapid tests at elevated temperatures
Haage, V. C., Ferreira de Oliveira-Filho, E., Moreira-Soto, A., Kühne, A., Fischer, C., Sacks, J., Corman, V. M., Müller, M. A., Drosten, C., Drexler, J. F.
10.1101/2021.01.06.21249314 — Posted: 2021-01-06
Fever, Diarrhea, and Severe Disease Correlate with High Persistent Antibody Levels against SARS-CoV-2
Amjadi, M. F., O'Connell, S. E., Armbrust, T., Mergaert, A. M., Narpala, S. R., Halfmann, P. J., Bashar, S. J., Glover, C. R., Heffron, A. S., Taylor, A., Flach, B., O'Connor, D. H., Kawaoka, Y., McDermott, A. B., Sethi, A. K., Shelef, M. A.
10.1101/2021.01.05.21249240 — Posted: 2021-01-06
THE INTESTINAL AND ORAL MICROBIOMES ARE ROBUST PREDICTORS OF COVID-19 SEVERITY THE MAIN PREDICTOR OF COVID-19-RELATED FATALITY
Ward, D. V., Bhattarai, S., Rojas-Correa, M., Purkayastha, A., Holler, D., Qu, M. D., Mitchell, W. G., Yang, J., Fountain, S., Zeamer, A., Forconi, C., Fujimori, G., Odwar, B., Cawley, C., McCormick, B. A., Moormann, A., Wessolossky, M., Bucci, V., Maldonado-Contreras, A.
10.1101/2021.01.05.20249061 — Posted: 2021-01-06
Long term impact on lung function of patients with moderate and severe COVID-19. A prospective cohort study
Qureshi, S., Nasir, N., Rashid, N., Ahmed, N., Haq, Z., Qamar, F. N.
10.1101/2021.01.06.21249312 — Posted: 2021-01-06
Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality
Silva, J., Lucas, C., Sundaram, M., Israelow, B., Wong, P., Klein, J., Tokuyama, M., Lu, P., Venkataraman, A., Liu, F., Mao, T., Oh, J. E., Park, A., Casanovas-Massana, a., Vogels, C. B. F., Muenker, C. M., Zell, J., Fournier, J. B., Campbell, M., Chiorazzi, M., Ruiz Fuentes, E., Yale IMPACT Team, , Grubaugh, N. D., Farhadian, S., Dela Cruz, C., Ko, A., Schulz, W. L., Ring, A. M., Ma, S., Omer, S., Wyllie, A. L., Iwasaki, A.
10.1101/2021.01.04.21249236 — Posted: 2021-01-06
Prevalence and Factors associated with Mental health impact of COVID-19 Pandemic in Bangladesh: A survey-based cross-sectional study
Abir, D. T., Kalimullah, D. N. A., Uchechukwu, D. L. O., Nur -A Yazdani, D. M., Husain, T., Goson, P. C., Basak, P., Rahman, M. A., Al Mamun, D. A., Permarupan, D. P. Y., Khan, M. Y. H., Milton, D. A. H., Agho, D. K.
10.1101/2021.01.05.21249216 — Posted: 2021-01-06
Twitter Discourse on Nicotine as Potential Prophylactic or Therapeutic for COVID-19
Kavuluru, R., Noh, J., Rose, S. W.
10.1101/2021.01.05.21249284 — Posted: 2021-01-06
Genomic epidemiology of the SARS-CoV-2 epidemic in Zimbabwe: Role of international travel and regional migration in spread
Mashe, T., Takawira, F. T., Martins, L. d. O., Gudza-Mugabe, M., Chirenda, J., Munyanyi, M., Gumbo, H., Chaibva, B. V., Nyagupe, C., Tarupiwa, A., Juru, A., Phiri, I., Manangazira, P., Goredema, A., Danda, S., Chabata, I., Jonga, J., Munharira, R., Masunda, K., Mukeredzi, I., Mangwanya, D., The COVID-19 Genomics UK (COG-UK) Consortium, , SARS-CoV-2 Research Group, , Trotter, A., Le Viet, T., Kay, G., Baker, D., Thilliez, G., Gutierrez, A.-V., O Grady, J., Hove, M., Mutapuri-Zinyowera, S., Page, A. J., Kingsley, R. A., Mhlanga, G.
10.1101/2021.01.04.20232520 — Posted: 2021-01-06
Machine Learning Forecast of Growth in COVID-19 Confirmed Infection Cases with Non-Pharmaceutical Interventions and Cultural Dimensions: Algorithm Development and Validation
Yeung, A. Y., Roewer-Despres, F., Rosella, L., Rudzicz, F.
10.1101/2021.01.04.21249235 — Posted: 2021-01-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).